Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of intravenous aprepitant for prevention of postoperative nausea and vomiting in adults
ChiCTR2400082488Phase 3Not yet recruiting
- Sponsor
- Third Xiangya Hospital, Central South University
- Start
- Mar 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of aprepitant in postoperative nausea and vomiting (PONV) (2 arms), sponsored by Third Xiangya Hospital, Central South University. Primary endpoint: Remission rate of postoperative nausea and vomiting. Planned start Mar 2024; status: not yet recruiting.
02
Drugs
aprepitant
03
Conditions
postoperative nausea and vomiting (PONV)
Beyond the preview
Go deeper on ChiCTR2400082488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400082488.